Form 4: ICU Medical CEO Vivek Jain Executes Stock Option and Sells Shares Under 10b5-1 Plan

ICU Medical's Chairman and CEO, Vivek Jain, exercised stock options and sold shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Vivek Jain, Chairman and CEO of ICU Medical, executed a series of transactions involving the company's stock on December 2, 2024.
• These transactions included the exercise of 12,000 non-qualified stock options at a price of $88.76 per share.
• Following the option exercise, Mr. Jain sold a total of 11,999 shares of common stock at weighted average prices ranging from $162.2884 to $163.96 per share.
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 15, 2024.
• After these transactions, Mr. Jain directly owns 104,593 shares and indirectly owns 88,698 shares through a trust.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by an executive under a pre-arranged plan, indicating a neutral sentiment.

Industry Context

This is a routine transaction for a company executive, and the use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies to manage their stock transactions.
• The reported prices are within the typical range for stock transactions of this nature.
• Similar transactions are regularly reported by executives at comparable companies such as Baxter International and Becton Dickinson.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy.
• The sales do not indicate any change in the company's performance or outlook.

Key Dates

Keywords

ICU Medical, Vivek Jain, stock options, share sales, Rule 10b5-1, insider trading, executive compensation